Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat disease based on its proprietary Esterase Motif Technology™ (ESM™) platform. ESM™ molecules deliver small molecule inhibitors of key intracellular targets in a highly selective manner to, monocytes, macrophages and dendritic cells. Macrophage Pharma is rapidly progressing its lead molecules to the clinic, initially utilising ESM™ to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment for cancer therapy. Macrophage involvement in a broad range of diseases means selective targeting with ESM™ also holds great promise in the treatment of inflammation, fibrosis and metabolic diseases.
The Company was founded by the CRT Pioneer Fund (CPF) and it subsequently announced the first close of a £9 million Series A financing round in November 2016. The round was led by CPF who were joined by two specialist investors, Novo Holdings A/S and Aglaia Biomedical Ventures BV. In July 2017, M Ventures BV invested in a second and final close of the Series A financing. The proceeds of the financing enable Macrophage Pharma to complete a first clinical study of its development candidate, MPL5821, a macrophage targeted p38MAP kinase inhibitor, as well as advancing an additional candidate against a second target into preclinical development. The company is also adding a third macrophage-targeted project into its pipeline, an ESM™ inhibitor against a novel inflammasome inhibitor.
The company’s management team has track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of our unique approach in immunotherapy.